Drug Profile
Research programme: central nervous system active peptides - Tetragenex
Alternative Names: INN 00955; INN 01134Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Tetragenex Pharmaceuticals
- Class Peptides
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Anxiety disorders; Major depressive disorder
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Anxiety-disorders in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Major depressive disorder in USA
- 31 Dec 2008 Preclinical trials in Anxiety disorders in USA (unspecified route)